ESR1 and breast carcinoma: Comparison of the poor prognosis group of the MP and the intermediate- and high-risk groups from the Oncotype DX recurrence-score (RS) models showed that their sample predictions agreed in 77% of patients with ER+ early-stage breast carcinomas.